Jazz Pharmaceuticals to Present Phase 3 Ziihera Data in HER2+ Gastroesophageal Adenocarcinoma at ASCO GI

Jazz Pharmaceuticals will present pivotal Phase 3 results of Ziihera (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium. The Phase 3 HERIZON-GEA-01 trial results demonstrate clinically meaningful improvements in progression-free survival and overall survival compared to the control arm. The company will also present a new post-hoc overall survival analysis from the HERIZON-BTC-01 Phase 2b trial in previously treated HER2+ biliary tract cancer.